| pubmed-article:3818941 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0023977 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
| pubmed-article:3818941 | lifeskim:mentions | umls-concept:C0549193 | lld:lifeskim |
| pubmed-article:3818941 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3818941 | pubmed:dateCreated | 1987-4-13 | lld:pubmed |
| pubmed-article:3818941 | pubmed:abstractText | Eleven patients with chronic progressive multiple sclerosis received monthly pulses of cyclophosphamide (CY) for approximately one year. During the final 9 months the monthly dose ranged between 1000 mg/m2 and 2000 mg/m2. This resulted in a marked (47% or greater) reduction in CD4 (T helper/inducer) cells a less striking (22%) decrease in CD8 (T suppressor/cytotoxic) cells and a decline in the CD4/CD8 ratio. The magnitude of the decrease in CD4 cells correlated with the total dose received (r = 0.88, P less than 0.05). B cells were reduced 50% and FcR+ lymphocytes were reduced 48% without comparable reduction in natural killer cells or antibody-dependent cellular cytotoxicity. Proliferative responses to PHA were suppressed. Two patients improved, seven stabilized and two continued to worsen. Monthly pulses of CY can achieve substantial and differential reduction in immune parameters and appear to slow the disease progression in some MS patients. | lld:pubmed |
| pubmed-article:3818941 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3818941 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3818941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3818941 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3818941 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:3818941 | pubmed:issn | 0165-5728 | lld:pubmed |
| pubmed-article:3818941 | pubmed:author | pubmed-author:MyersL WLW | lld:pubmed |
| pubmed-article:3818941 | pubmed:author | pubmed-author:EllisonG WGW | lld:pubmed |
| pubmed-article:3818941 | pubmed:author | pubmed-author:KaganJJ | lld:pubmed |
| pubmed-article:3818941 | pubmed:author | pubmed-author:LiaoDD | lld:pubmed |
| pubmed-article:3818941 | pubmed:author | pubmed-author:MoodyD JDJ | lld:pubmed |
| pubmed-article:3818941 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3818941 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:3818941 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3818941 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3818941 | pubmed:pagination | 161-73 | lld:pubmed |
| pubmed-article:3818941 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:meshHeading | pubmed-meshheading:3818941-... | lld:pubmed |
| pubmed-article:3818941 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3818941 | pubmed:articleTitle | Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters. | lld:pubmed |
| pubmed-article:3818941 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3818941 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3818941 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3818941 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3818941 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3818941 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3818941 | lld:pubmed |
